Optinose - Margin dodolan resik OPTN

Optinose - logo grafis emiten OPTN

The expansion of XHANCE commercial reach in treating rhinosinusitis drives momentum where the net profit margin visualizes the business's actual yield for OptiNose, Inc. (OPTN). The EDS system and XHANCE device ensure deep drug penetration into the sinuses, while integration with anti-polyp agents establishes a standard for ENT therapy. The value of -36.60 represents the current metric, allowing a distinction between a sustainable profitability trend and random spikes.

Rentabilitas dodolan resik OptiNose, Inc. (OPTN): kanggo periode 04.07.2022 - 31.05.2025

Ringkesan rincian data analitis Optinose (OPTN)

- rega saham lan konsensus proyeksi valuasi:
Analisis komprehensif perusahaan:OptiNose, OPTN
Produk asil prodhuksi OptiNose Inc

Identifying sustainable assets requires separating long-term trends from market noise. Net profit margin measures the portion of profit remaining from every dollar of revenue after all expenses. For OptiNose, Inc. (OPTN), this calculation demonstrates the efficiency of commercializing drug delivery systems amid growing demand for rhinosinusitis treatment. Positive momentum in the net profit margin confirms the scalability of the business model. Investors should use this chart to assess the operational resilience of the issuer.

Karo sapa OptiNose, Inc. saingan

HLN: Margin dodolan resik|Rentabilitas dodolan resik KVUE|Margin resik veronapharma.com|Rentabilitas dodolan resik MENS (Jyong Biotech Corp)|Margin resik Ligand (LGND)|Margin dodolan resik amneal.com (AMRX)|Margin dodolan resik PRGO (perrigo.com)|Alvotech SA (ALVO) - Margin resik|Liquidia Inc. - Margin dodolan resik|Tingkat bathi miturut bathi resik Galapagos Corp (GLPG)|ANI Pharmaceuticals (ANIP) - Margin resik|Rentabilitas dodolan resik MNKD|Margin resik Amphastar Pharmaceuticals, Inc.|Pacira Pharmaceuticals (PCRX) - Margin dodolan perusahaan|Margin dodolan resik SPRY|TBPH - Margin resik|Aquestive Pharma - Rentabilitas dodolan miturut bathi resik|Margin dodolan resik scpharmaceuticals.com SCPH|Tectonic - Margin dodolan resik|TNXP - Margin dodolan resik|SXTC: Margin dodolan resik|Eupraxia Pharma - Tingkat bathi resik|BHST (bioharvest.com) - Margin dodolan resik|Rentabilitas dodolan resik EXOZ (invizyne.com)|Margin dodolan resik ORMP|Margin dodolan perusahaan Entera Bio|Margin dodolan resik HYFT (MindWalk Holdings, Inc.)|ABVC BioPharma - Margin resik|Cumberland Corp - Margin dodolan resik|QNTM - Margin dodolan resik|FibroGen, Inc. (FGEN) - Margin resik|TELO: Rentabilitas resik perusahaan|RANI (Rani Therapeutics Inc) - Margin dodolan resik|Margin resik synergychc.com SNYR|Margin resik Rallybio Corp. (RLYB)|LEXX - Margin resik|Margin dodolan resik PULM (pulmatrix.com)|Rentabilitas resik perusahaan PTHL (Pheton)|APM - Margin resik|Margin dodolan perusahaan Lyra Therapeutics Inc LYRA|impactbiomedinc.com (IBO) - Margin resik|TNF Pharma (TNFA) - Margin dodolan resik|YCBD (cbdmd.com) - Margin dodolan resik|Rentabilitas dodolan miturut bathi resik PainReform (PRFX)|Margin resik Altamira Therapeutics (CYTO)|Margin dodolan perusahaan Lipella Pharma|Margin resik pieris.com PIRS|Tingkat bathi resik PROC|PTPI - Margin resik|Qilian International Holding (QLI) - Rentabilitas dodolan miturut bathi resik|SLRN: Margin dodolan resik|Rentabilitas dodolan miturut bathi resik TFF Pharma